Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Gensia Pharmaceuticals Inc., Marion Merrell Dow Inc. deal

MMD decided not to exercise its option on GNSA's adenosine compound GP-1-531 for cardiovascular use. MMD spokesperson Charles

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE